[3] demonstrated the successful development of trastuzumab–PROTAC conjugates that selectively degrade BRD4 only in HER2‐positive breast cancer cells while sparing HER2‐negative cells, achieving stable drug‐to‐antibody ratios of 4 with excellent serum stability. This evidence concerns the gene ERBB2 and breast carcinoma.